CLNICAL EFFICACY OF VEL-CTD (BORTEZOMIB, CYCLOPHOSPHAMIDE, THALIDOMIDE, AND DEXAMETHASONE) REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE II STUDY

被引：0
|
作者：
Kim, Y. K. [1 ]
Ahn, J. S. [1 ]
Yang, D. H. [1 ]
Sohn, S. K. [2 ]
Moon, J. H. [2 ]
Kim, H. J. [1 ]
Shin, H. J. [3 ]
Chung, J. S. [3 ]
Choi, Y. J. [3 ]
Chae, Y. S. [2 ]
Kim, J. G. [2 ]
Lee, J. H. [4 ]
Lee, J. J. [1 ]
机构：
[1] Chonnam Natl Univ, Sch Med, Kwangju, South Korea
[2] Kyungpook Natl Univ, Sch Med, Taegu, South Korea
[3] Pusan Natl Univ, Sch Med, Pusan, South Korea
[4] Gachon Univ, Gil Med Ctr, Inchon, South Korea
[5] KMMWP, Seoul, South Korea
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0951
引用
收藏
页码：383 / 383
页数：1
相关论文
共 50 条
  • [1] Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
    Kim, Yeo-Kyeoung
    Sohn, Sang-Kyun
    Lee, Jae-Hoon
    Yang, Deok-Hwan
    Moon, Joon-Ho
    Ahn, Jae-Sook
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    ANNALS OF HEMATOLOGY, 2010, 89 (05) : 475 - 482
  • [2] Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
    Yeo-Kyeoung Kim
    Sang-Kyun Sohn
    Jae-Hoon Lee
    Deok-Hwan Yang
    Joon-Ho Moon
    Jae-Sook Ahn
    Hyeoung-Joon Kim
    Je-Jung Lee
    Annals of Hematology, 2010, 89 : 475 - 482
  • [3] A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Jung, Sung-Hoon
    Park, Hyung Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Bae, Soo-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    ANNALS OF HEMATOLOGY, 2012, 91 (07) : 1023 - 1030
  • [4] A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma
    Jae-Sook Ahn
    Deok-Hwan Yang
    Sung-Hoon Jung
    Hyung Chul Park
    Joon Ho Moon
    Sang Kyun Sohn
    Soo-Young Bae
    Yeo-Kyeoung Kim
    Hyeoung-Joon Kim
    Je-Jung Lee
    Annals of Hematology, 2012, 91 : 1023 - 1030
  • [5] Clinical Efficacy of a Bortezomib, Cyclophosphamide and Dexamethasone Compared with Bortezomib, Cyclophosphamide, Thalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Moon, Joon Ho
    Sohn, Sang Kyun
    Jung, Sung-Hoon
    Bae, Soo-Young
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BLOOD, 2011, 118 (21) : 815 - 815
  • [6] Phase II study of thalidomide with dexamethasone for relapsed/refractory multiple myeloma
    Kinoshita, T
    Ohno, T
    Yuge, M
    Hiraga, J
    Matsushita, T
    Ando, S
    Naoe, T
    ANNALS OF ONCOLOGY, 2005, 16 : 206 - 206
  • [7] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study
    Richardson, Paul
    Jagannath, Sundaf
    Raje, Noopur
    Jakubowiak, Andrzej
    Lonial, Sagar
    Ghobrial, Irene
    Schlossman, Robert
    Mazumder, Amitabha
    Munshi, Nikhil
    Colson, Kathleen
    McKenney, Mary
    Farrell, Melissa
    Lunde, Laura
    Giove, Lawrence
    Kaster, Sarah
    Mitsiades, Constantine
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth
    BLOOD, 2007, 110 (11) : 797A - 797A
  • [8] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    Offidani, M.
    Corvatta, L.
    Maracci, L.
    Liberati, A. M.
    Ballanti, S.
    Attolico, I.
    Caraffa, P.
    Alesiani, F.
    di Toritto, T. Caravita
    Gentili, S.
    Tosi, P.
    Brunori, M.
    Derudas, D.
    Ledda, A.
    Gozzetti, A.
    Cellini, C.
    Malerba, L.
    Mele, A.
    Andriani, A.
    Galimberti, S.
    Mondello, P.
    Pulini, S.
    Coppetelli, U.
    Fraticelli, P.
    Olivieri, A.
    Leoni, P.
    BLOOD CANCER JOURNAL, 2013, 3 : e162 - e162
  • [9] Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study
    M Offidani
    L Corvatta
    L Maracci
    A M Liberati
    S Ballanti
    I Attolico
    P Caraffa
    F Alesiani
    T Caravita di Toritto
    S Gentili
    P Tosi
    M Brunori
    D Derudas
    A Ledda
    A Gozzetti
    C Cellini
    L Malerba
    A Mele
    A Andriani
    S Galimberti
    P Mondello
    S Pulini
    U Coppetelli
    P Fraticelli
    A Olivieri
    P Leoni
    Blood Cancer Journal, 2013, 3 : e162 - e162
  • [10] Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
    Gleason, Charise
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Valla, Kelly
    Heffner, Leonard T.
    Bisht, Aditya Singh
    Manubolu, Sanjay
    Watson, Melanie
    Boise, Lawrence H.
    Lonial, Sagar
    BLOOD, 2014, 124 (21)
12345